PharmaCyte Biotech Inc (PMCB)

[CIDJAMES]

Nuvilex, Inc. (OTCQB: NVLX) introduced their advanced pancreatic cancer treatment to the U.S FDA in an application for orphan drug designation for their Cell-in-a-Box®/ifosfamide combination treatment.

Marketing exclusivity attracts Big Pharma

If Nuvilex is granted orphan drug designation in the U.S. and Europe, NVLX would receive 7 and 10 years, respectively, of marketing exclusivity for their their pancreatic cancer treatment without any competition. This marketing exclusivity makes smaller biotechnology firms attractive to Big Pharma.